| 96 |
Potent P2Y12 Inhibitors for East-Asian Patients: Insights from the TWIGHLIGHT in Western vs. Asian Population |
Roxana Mehran |
Apr. 12. 21 |
| 95 |
\"Less is More\" in Antithrombotic Therapy After PCI: Clinically Relevant not only in East-Asian but also in Western Population |
Takeshi Kimura |
Apr. 12. 21 |
| 94 |
Antithrombotic Therapy in East Asian with ACS/PCI: Updated Evidences for East-Asian Paradox |
Glenn N. Levine |
Apr. 12. 21 |
| 93 |
Composite Outcomes and Net Adverse Events: Implications for Trial Design and Interpretation |
David Joel Cohen |
Apr. 12. 21 |
| 92 |
Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial |
Duk-Woo Park |
Apr. 12. 21 |
| 91 |
Short DAPT Followed by P2Y12 Monotherapy: New Trend Updates with Clinical Evidences |
Davide Capodanno |
Apr. 12. 21 |
| 90 |
Tailored Antithrombotic Strategy for CHIP and HBR Patients - How To Do? |
Philip M. Urban |
Apr. 12. 21 |
| 89 |
Evolving Antithrombotic Strategies for Patients with DM and CAD |
Dominick J. Angiolillo |
Apr. 12. 21 |
| 88 |
Shorter DAPT vs. Longer DAPT: Whom and How? - Clinician\'s and Trialist\'s Perspective |
Robert W. Yeh |
Apr. 12. 21 |
| 87 |
Antithrombotic Strategy in PCI and AF Patients: Updated Strategy |
Alan C. Yeung |
Nov. 27. 19 |
